Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program

Peter J. Houghton, Christopher L. Morton, Richard Gorlick, E. Anders Kolb, Stephen T. Keir, C. Patrick Reynolds, Min H. Kang, John M. Maris, Jianrong Wu, Malcolm A. Smith

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Background. Many childhood malignancies including sarcomas, neuroblastoma, and Wilms tumor show the presence of both, active, type-1-insulin-like growth factor receptor (IGF-1R), and the autocrine production of its ligands IGF-1/IGF-2. IMC-A12 is a fully human IgG1 antibody that prevents ligand binding to the IGF-1R. Procedures. IMC-A12 was evaluated against the 23 cell lines of the Pediatric Preclinical Testing Program (PPTP) in vitro panel using 96 hr exposure at concentrations ranging from 0.01nM to 0.1 μM. IMC-A12 was tested in vivo at a dose of 1 mg/mouse administered intraperitoneally twice weekly for 6 weeks. Results. In vitro, IMC-A12-induced T/C values <50% in only three cell lines, a rhabdomyosarcoma cell line (Rh41) and two Ewing sarcoma cell lines (TC-71 and CHLA-9). In vivo, IMC-A12 induced significant differences in EFS distribution compared to control in 24 of 34 (71%) evaluable solid tumor xenografts. Using the PPTP "time to event" activity measure, IMC-A12 induced intermediate (n = 13) or high (n = 1) activity in 33 xenografts evaluable for this activity measure, including 6 of 6 rhabdomyosarcoma xenografts, 3 of 5 osteosarcoma xenografts, 2 of 5 neuroblastoma xenografts, and 1 of 5 Ewing sarcoma xenografts. The only objective response observed was observed in a rhabdomyosarcoma xenograft (Rh28) that achieved a maintained complete response. Conclusions. IMC-A12 demonstrated broad antitumor activity against the PPTP's in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression. IMC-A12 showed its greatest activity in vivo against the PPTP's rhabdomyosarcoma xenografts.

Original languageEnglish (US)
Pages (from-to)921-926
Number of pages6
JournalPediatric Blood and Cancer
Volume54
Issue number7
DOIs
StatePublished - Jul 1 2010

Fingerprint

Heterografts
Monoclonal Antibodies
Pediatrics
Rhabdomyosarcoma
Cell Line
Ewing's Sarcoma
Neoplasms
Neuroblastoma
Ligands
IGF Type 1 Receptor
Insulin-Like Growth Factor II
Wilms Tumor
anti-IGF-1R antibody A12
Osteosarcoma
Insulin-Like Growth Factor I
Sarcoma
Immunoglobulin G
Antibodies
Growth

Keywords

  • Developmental therapeutics
  • IMC-A12
  • Preclinical testing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Houghton, P. J., Morton, C. L., Gorlick, R., Kolb, E. A., Keir, S. T., Reynolds, C. P., ... Smith, M. A. (2010). Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program. Pediatric Blood and Cancer, 54(7), 921-926. https://doi.org/10.1002/pbc.22367

Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program. / Houghton, Peter J.; Morton, Christopher L.; Gorlick, Richard; Kolb, E. Anders; Keir, Stephen T.; Reynolds, C. Patrick; Kang, Min H.; Maris, John M.; Wu, Jianrong; Smith, Malcolm A.

In: Pediatric Blood and Cancer, Vol. 54, No. 7, 01.07.2010, p. 921-926.

Research output: Contribution to journalArticle

Houghton, PJ, Morton, CL, Gorlick, R, Kolb, EA, Keir, ST, Reynolds, CP, Kang, MH, Maris, JM, Wu, J & Smith, MA 2010, 'Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 54, no. 7, pp. 921-926. https://doi.org/10.1002/pbc.22367
Houghton, Peter J. ; Morton, Christopher L. ; Gorlick, Richard ; Kolb, E. Anders ; Keir, Stephen T. ; Reynolds, C. Patrick ; Kang, Min H. ; Maris, John M. ; Wu, Jianrong ; Smith, Malcolm A. / Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2010 ; Vol. 54, No. 7. pp. 921-926.
@article{afcb7c2f6f314d96ab5746f80e1d63e5,
title = "Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program",
abstract = "Background. Many childhood malignancies including sarcomas, neuroblastoma, and Wilms tumor show the presence of both, active, type-1-insulin-like growth factor receptor (IGF-1R), and the autocrine production of its ligands IGF-1/IGF-2. IMC-A12 is a fully human IgG1 antibody that prevents ligand binding to the IGF-1R. Procedures. IMC-A12 was evaluated against the 23 cell lines of the Pediatric Preclinical Testing Program (PPTP) in vitro panel using 96 hr exposure at concentrations ranging from 0.01nM to 0.1 μM. IMC-A12 was tested in vivo at a dose of 1 mg/mouse administered intraperitoneally twice weekly for 6 weeks. Results. In vitro, IMC-A12-induced T/C values <50{\%} in only three cell lines, a rhabdomyosarcoma cell line (Rh41) and two Ewing sarcoma cell lines (TC-71 and CHLA-9). In vivo, IMC-A12 induced significant differences in EFS distribution compared to control in 24 of 34 (71{\%}) evaluable solid tumor xenografts. Using the PPTP {"}time to event{"} activity measure, IMC-A12 induced intermediate (n = 13) or high (n = 1) activity in 33 xenografts evaluable for this activity measure, including 6 of 6 rhabdomyosarcoma xenografts, 3 of 5 osteosarcoma xenografts, 2 of 5 neuroblastoma xenografts, and 1 of 5 Ewing sarcoma xenografts. The only objective response observed was observed in a rhabdomyosarcoma xenograft (Rh28) that achieved a maintained complete response. Conclusions. IMC-A12 demonstrated broad antitumor activity against the PPTP's in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression. IMC-A12 showed its greatest activity in vivo against the PPTP's rhabdomyosarcoma xenografts.",
keywords = "Developmental therapeutics, IMC-A12, Preclinical testing",
author = "Houghton, {Peter J.} and Morton, {Christopher L.} and Richard Gorlick and Kolb, {E. Anders} and Keir, {Stephen T.} and Reynolds, {C. Patrick} and Kang, {Min H.} and Maris, {John M.} and Jianrong Wu and Smith, {Malcolm A.}",
year = "2010",
month = "7",
day = "1",
doi = "10.1002/pbc.22367",
language = "English (US)",
volume = "54",
pages = "921--926",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "7",

}

TY - JOUR

T1 - Initial testing of a monoclonal antibody (IMC-A12) against IGF-1R by the pediatric preclinical testing program

AU - Houghton, Peter J.

AU - Morton, Christopher L.

AU - Gorlick, Richard

AU - Kolb, E. Anders

AU - Keir, Stephen T.

AU - Reynolds, C. Patrick

AU - Kang, Min H.

AU - Maris, John M.

AU - Wu, Jianrong

AU - Smith, Malcolm A.

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Background. Many childhood malignancies including sarcomas, neuroblastoma, and Wilms tumor show the presence of both, active, type-1-insulin-like growth factor receptor (IGF-1R), and the autocrine production of its ligands IGF-1/IGF-2. IMC-A12 is a fully human IgG1 antibody that prevents ligand binding to the IGF-1R. Procedures. IMC-A12 was evaluated against the 23 cell lines of the Pediatric Preclinical Testing Program (PPTP) in vitro panel using 96 hr exposure at concentrations ranging from 0.01nM to 0.1 μM. IMC-A12 was tested in vivo at a dose of 1 mg/mouse administered intraperitoneally twice weekly for 6 weeks. Results. In vitro, IMC-A12-induced T/C values <50% in only three cell lines, a rhabdomyosarcoma cell line (Rh41) and two Ewing sarcoma cell lines (TC-71 and CHLA-9). In vivo, IMC-A12 induced significant differences in EFS distribution compared to control in 24 of 34 (71%) evaluable solid tumor xenografts. Using the PPTP "time to event" activity measure, IMC-A12 induced intermediate (n = 13) or high (n = 1) activity in 33 xenografts evaluable for this activity measure, including 6 of 6 rhabdomyosarcoma xenografts, 3 of 5 osteosarcoma xenografts, 2 of 5 neuroblastoma xenografts, and 1 of 5 Ewing sarcoma xenografts. The only objective response observed was observed in a rhabdomyosarcoma xenograft (Rh28) that achieved a maintained complete response. Conclusions. IMC-A12 demonstrated broad antitumor activity against the PPTP's in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression. IMC-A12 showed its greatest activity in vivo against the PPTP's rhabdomyosarcoma xenografts.

AB - Background. Many childhood malignancies including sarcomas, neuroblastoma, and Wilms tumor show the presence of both, active, type-1-insulin-like growth factor receptor (IGF-1R), and the autocrine production of its ligands IGF-1/IGF-2. IMC-A12 is a fully human IgG1 antibody that prevents ligand binding to the IGF-1R. Procedures. IMC-A12 was evaluated against the 23 cell lines of the Pediatric Preclinical Testing Program (PPTP) in vitro panel using 96 hr exposure at concentrations ranging from 0.01nM to 0.1 μM. IMC-A12 was tested in vivo at a dose of 1 mg/mouse administered intraperitoneally twice weekly for 6 weeks. Results. In vitro, IMC-A12-induced T/C values <50% in only three cell lines, a rhabdomyosarcoma cell line (Rh41) and two Ewing sarcoma cell lines (TC-71 and CHLA-9). In vivo, IMC-A12 induced significant differences in EFS distribution compared to control in 24 of 34 (71%) evaluable solid tumor xenografts. Using the PPTP "time to event" activity measure, IMC-A12 induced intermediate (n = 13) or high (n = 1) activity in 33 xenografts evaluable for this activity measure, including 6 of 6 rhabdomyosarcoma xenografts, 3 of 5 osteosarcoma xenografts, 2 of 5 neuroblastoma xenografts, and 1 of 5 Ewing sarcoma xenografts. The only objective response observed was observed in a rhabdomyosarcoma xenograft (Rh28) that achieved a maintained complete response. Conclusions. IMC-A12 demonstrated broad antitumor activity against the PPTP's in vivo solid tumor panels, with the activity primarily being tumor growth inhibition rather than tumor regression. IMC-A12 showed its greatest activity in vivo against the PPTP's rhabdomyosarcoma xenografts.

KW - Developmental therapeutics

KW - IMC-A12

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=77951747892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951747892&partnerID=8YFLogxK

U2 - 10.1002/pbc.22367

DO - 10.1002/pbc.22367

M3 - Article

C2 - 20166202

AN - SCOPUS:77951747892

VL - 54

SP - 921

EP - 926

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 7

ER -